RxDoctor Payments Data

Lisa Raymond-Prinz, NP

Acute Care · Covington, LANPI 1033766498

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 53.9% of the total.

$2,773in general payments, 2019–2025

Across 164 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$350
  • Phathom Pharmaceuticals, Inc.$200
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$179
  • Ardelyx, Inc.$164
  • Takeda Pharmaceuticals U.S.A., Inc.$87
  • plus $299 from 9 others

What the payments were for

  • Food & beverage$2,74899%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,773 in reported general payments places this provider in the 80th percentile of 248 acute care providers in Louisiana.

See all acute care providers in Louisiana

Medicare billing

Part B allowed, 2024
$8,622
Medicare patients
83
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide128$83,374
CreonLipase/Protease/Amylase18$33,978
TrulancePlecanatide19$21,325
MotegrityPrucalopride Succinate25$12,478
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates135$9,019
Sucralfate99$3,474
Dexlansoprazole DrDexlansoprazole11$2,695
Omeprazole181$2,420
Pantoprazole Sodium377$2,119
Famotidine97$1,910
Colestipol Hcl19$1,699
CholestyramineCholestyramine (With Sugar)13$1,336
Esomeprazole Magnesium35$1,011
Lubiprostone15$930
Rabeprazole Sodium37$741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,495$117,352146 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$179$21,32519 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$87$12,47825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 248 acute care providers in Louisiana.

Other acute care in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →